Tough Q1 In US For Glenmark, Eyes on Ryaltris Debut, Flovent Rival Filing
Teva Believed To Be Sole Other Flovent ANDA Filer
Glenmark signals “very challenging” US environment but expects things to stabilize with a string of potential new launches in the wings. The impending debut of Ryaltris, among other products, and a filing for a generic rival to Flovent could add some spark to the US business.
